Coelho, Teresa
Yarlas, Aaron http://orcid.org/0000-0003-4600-259X
Waddington-Cruz, Marcia
White, Michelle K.
Sikora Kessler, Asia
Lovley, Andrew
Pollock, Michael
Guthrie, Spencer
Ackermann, Elizabeth J.
Hughes, Steven G.
Karam, Chafic
Khella, Sami
Gertz, Morie
Merlini, Giampaolo
Obici, Laura
Schmidt, Hartmut H.
Polydefkis, Michael
Dyck, P. James B.
Brannagan III, Thomas H.
Conceição, Isabel
Benson, Merrill D.
Berk, John L.
Funding for this research was provided by:
Akcea Therapeutics (N/A)
Ionis Pharmaceuticals (N/A)
Article History
Received: 23 October 2019
Revised: 6 December 2019
Accepted: 9 December 2019
First Online: 18 December 2019
Compliance with ethical standards
:
: Coelho<b>,</b> Prothena: consultancy, honoraria; Ionis: consultancy, other: investigator; Alnylam: consultancy, honoraria, other: investigator; Pfizer: consultancy, honoraria, other: investigator. Yarlas, Lovley, Sikora Kessler, and White are employees of Optum, which received payment from Akcea Therapeutics and Ionis Pharmaceuticals Inc. to conduct these analyses and develop this manuscript. Waddington Cruz: Ionis: honoraria; Genzyme/Sanofi: honoraria; Pfizer: honoraria. Pollock is an employee of and owns stock in Akcea Therapeutics. Guthrie was an employee of and owned stock in Akcea Therapeutics. Ackermann, Akcea: consultancy. Hughes is a former employee of and owns stock in Ionis Pharmaceuticals, Inc. Karam, Acceleron: consultancy; Akcea: consultancy; Alexion: consultancy; Alnylam: consultancy; Biogen: consultancy; Cytokinetics: consultancy; CSL Behring: consultancy, Sanofi Genzyme: consultancy. Khella: Akcea: consultancy; Alnylam: consultancy; Pfizer: consultancy. Gertz: Janssen: consultancy; Teva: consultancy; Spectrum: consultancy, honoraria; Alnylam: honoraria; Ionis: honoraria; Amgen: consultancy; Annexon: consultancy; Prothena: honoraria; research to practice: consultancy; Apellis: consultancy; Celgene: consultancy; Abbvie: consultancy; Medscape: consultancy; Physicians Education Resource: consultancy. Merlini: no relationships to disclose. Obici, has received speaking and consulting fees from Akcea, Pfizer and Alnylam. Schmidt, Akcea: consultancy; Alnylam: consultancy; Pfizer: consultancy. Polydefkis, Pfizer: honoraria; Alnylam: honoraria. Dyck, Ionis: consultancy; Alnylam: consultancy. Brannagan, Alnylam: honoraria, other: investigator, Speakers Bureau; Ionis: honoraria, consultancy, speaking, other: investigator. Conceição, Ionis: other: investigator; Alnylam: consultancy, honoraria, other: investigator; Pfizer: consultancy, honoraria, other: investigator. Benson, Ionis: other: investigator, research funding. Berk, Ionis: honoraria, other: investigator; Alnylam: honoraria, other: investigator; Pfizer<i>:</i> other: investigator.
: The trial protocol was approved by institutional review boards or local ethics committees. The trial was conducted in accordance with Good Clinical Practice guidelines of the International Conference on Harmonisation and the principles of the Declaration of Helsinki. All the patients provided written informed consent to participate in the trial.